9月2日，10x Genomics盘中上涨5.59%，报63.33美元/股，成交额944.08万美元。
消息面上，加拿大皇家银行（RBC Capital Markets）首次覆盖10x Genomics，给予行业持平评级，目标价70美元，远高于FactSet统计的分析师平均目标价51美元。RBC指出，公司在高通量空间分子分析领域处于领先地位，市场份额超60%，空间业务仍处于早期渗透阶段，保持双位数增长；但单细胞业务因单反应价格双位数下滑，构成结构性增长拖累。RBC认为单细胞业务需实现"有意义"的增长，才能推动整体估值进一步提升。此外，公司近期Q2财报营收1.51亿美元超预期，全年指引上调至6.1亿至6.3亿美元，基本面改善亦提供支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.